RTNXF (Renalytix) Pre-Tax Income : $-28.68 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Renalytix Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Renalytix's pretax income for the three months ended in Sep. 2024 was $-4.73 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-28.68 Mil. Renalytix's pretax margin was -905.36%.

During the past 7 years, Renalytix's highest Pretax Margin was -1221.61%. The lowest was -2400.47%. And the median was -1492.46%.

Renalytix Pre-Tax Income Historical Data

The historical data trend for Renalytix's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Pre-Tax Income Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Pre-Tax Income

Get a 7-Day Free Trial

-9.84

-35.79

-45.25

-45.61

-33.45

Renalytix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial															-10.15	-9.13	-7.74	-7.07	-4.73

Competitive Comparison of Renalytix's Pre-Tax Income

For the Health Information Services subindustry, Renalytix's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix's Pre-Tax Income Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Renalytix's Pre-Tax Income falls into.

Renalytix Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Renalytix's Pretax Income for the fiscal year that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-28.885	+	0	+	0	+	0	+	-4.567
	=	-33.45

Renalytix's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-4.092	+	0	+	0	+	0	+	-0.634
	=	-4.73

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.68 Mil.

Renalytix (OTCPK:RTNXF) Pre-Tax Income Explanation

Renalytix's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-4.726	/	0.522
	=	-905.36%

During the past 7 years, Renalytix's highest Pretax Margin was -1221.61%. The lowest was -2400.47%. And the median was -1492.46%.

Renalytix Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Renalytix's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (OTCPK:RTNXF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

RNLXY:USA RENX:UK 2O9A:Germany

Address

2 Leman Street, London, GBR, E1W 9US

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.